These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17219761)

  • 21. [HIV-1 fusion inhibitor improves treatment in HIV-1-resistant patients].
    Blasko M
    Dtsch Med Wochenschr; 2003 May; 128(19):1032. PubMed ID: 12774800
    [No Abstract]   [Full Text] [Related]  

  • 22. Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide.
    Loutfy MR; Raboud JM; Montaner JS; Antoniou T; Wynhoven B; Smaill F; Rouleau D; Gill J; Schlech W; Brumme ZL; Mo T; Gough K; Rachlis A; Harrigan PR; Walmsley SL
    Antiviral Res; 2007 Jul; 75(1):58-63. PubMed ID: 17196268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of imputation and modelling methods in the analysis of a physical activity trial with missing outcomes.
    Wood AM; White IR; Hillsdon M; Carpenter J
    Int J Epidemiol; 2005 Feb; 34(1):89-99. PubMed ID: 15333619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modelling the effects of adherence to the HIV fusion inhibitor enfuvirtide.
    Lou J; Smith RJ
    J Theor Biol; 2011 Jan; 268(1):1-13. PubMed ID: 20888346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.
    Wheeler DA; Lalezari JP; Kilby JM; Wheat J; Delehanty J; DeMasi R; Patel I; Salgo M
    J Clin Virol; 2004 Jun; 30(2):183-90. PubMed ID: 15125875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
    Gallien S; Braun J; Delaugerre C; Charreau I; Reynes J; Jeanblanc F; Verdon R; de Truchis P; May T; Madelaine-Chambrin I; Aboulker JP; Molina JM;
    J Antimicrob Chemother; 2011 Sep; 66(9):2099-106. PubMed ID: 21712241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-line use of enfuvirtide-containing HAART regimen with dramatic clinical and immunological improvement in three cases.
    Bourgarit A; Lascoux C; Palmer P; Tuleja E; Pintado C; Farge D; Sereni D
    AIDS; 2006 Feb; 20(3):471-3. PubMed ID: 16439888
    [No Abstract]   [Full Text] [Related]  

  • 28. [Fusion inhibitors. One year therapy with T-20--initial evaluation].
    Goebel FD
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046
    [No Abstract]   [Full Text] [Related]  

  • 29. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
    De Castro N; Braun J; Charreau I; Pialoux G; Cotte L; Katlama C; Raffi F; Weiss L; Meynard JL; Yazdanpanah Y; Delaugerre C; Madelaine-Chambrin I; Aboulker JP; Molina JM;
    Clin Infect Dis; 2009 Oct; 49(8):1259-67. PubMed ID: 19757993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of the random-effects pattern mixture model with last-observation-carried-forward (LOCF) analysis in longitudinal clinical trials with dropouts.
    Siddiqui O; Ali MW
    J Biopharm Stat; 1998 Nov; 8(4):545-63. PubMed ID: 9855033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3253-9. PubMed ID: 15328081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.
    Aquaro S; D'Arrigo R; Svicher V; Perri GD; Caputo SL; Visco-Comandini U; Santoro M; Bertoli A; Mazzotta F; Bonora S; Tozzi V; Bellagamba R; Zaccarelli M; Narciso P; Antinori A; Perno CF
    J Antimicrob Chemother; 2006 Oct; 58(4):714-22. PubMed ID: 16891628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A structured framework for assessing sensitivity to missing data assumptions in longitudinal clinical trials.
    Mallinckrodt CH; Lin Q; Molenberghs M
    Pharm Stat; 2013; 12(1):1-6. PubMed ID: 23193075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide.
    Walmsley S; Henry K; Katlama C; Nelson M; Castagna A; Reynes J; Clotet B; Hui J; Salgo M; DeMasi R; Delehanty J
    J Infect Dis; 2003 Dec; 188(12):1827-33. PubMed ID: 14673761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enfuvirtide doubles chances for suppression.
    AIDS Patient Care STDS; 2004 Sep; 18(9):550. PubMed ID: 15630779
    [No Abstract]   [Full Text] [Related]  

  • 36. Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.
    Charpentier C; Jenabian MA; Piketty C; Karmochkine M; Tisserand P; Laureillard D; Bélec L; Si-Mohamed A; Weiss L
    Scand J Infect Dis; 2011 May; 43(5):373-9. PubMed ID: 21341978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.
    Cervia JS; Smith MA
    Clin Infect Dis; 2003 Oct; 37(8):1102-6. PubMed ID: 14523775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.
    Su C; Melby T; DeMasi R; Ravindran P; Heilek-Snyder G
    J Clin Virol; 2006 Aug; 36(4):249-57. PubMed ID: 16765082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The suppression of immune activation during enfuvirtide-based salvage therapy is associated with reduced CCR5 expression and decreased concentrations of circulating interleukin-12 and IP-10 during 48 weeks of longitudinal follow-up.
    Carsenti-Dellamonica H; Saïdi H; Ticchioni M; Guillouet de Salvador F; Dufayard Cottalorda J; Garraffo R; Dellamonica P; Durant J; Gougeon ML
    HIV Med; 2011 Feb; 12(2):65-77. PubMed ID: 20500532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The introduction of the fusion inhibitors in the HAART-regimens.
    Hasson H; Castagna A; Clementi M; Menzo S; Danise A; Lazzarin A
    New Microbiol; 2004 Apr; 27(2 Suppl 1):11-6. PubMed ID: 15646060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.